Compare PLNT & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLNT | CYTK |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.0B |
| IPO Year | 2015 | 2004 |
| Metric | PLNT | CYTK |
|---|---|---|
| Price | $97.35 | $62.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $118.83 | $82.38 |
| AVG Volume (30 Days) | 1.7M | ★ 2.2M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.23 | N/A |
| EPS | ★ 2.44 | N/A |
| Revenue | ★ $1,202,700,000.00 | $87,211,000.00 |
| Revenue This Year | $21.43 | $339.72 |
| Revenue Next Year | $11.05 | $79.08 |
| P/E Ratio | $40.03 | ★ N/A |
| Revenue Growth | 14.63 | ★ 2609.26 |
| 52 Week Low | $87.72 | $29.31 |
| 52 Week High | $114.47 | $70.98 |
| Indicator | PLNT | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 30.62 | 47.75 |
| Support Level | $98.26 | $60.30 |
| Resistance Level | $108.49 | $65.08 |
| Average True Range (ATR) | 3.51 | 2.91 |
| MACD | -1.24 | -0.01 |
| Stochastic Oscillator | 12.45 | 45.74 |
Planet Fitness Inc is a franchisor and operator of fitness centers in the United States. The company's reportable segments are Franchise, Corporate-owned stores, and Equipment. Franchise segment includes operations related to its franchising business in the United States, Puerto Rico, Canada, Panama, Mexico and Australia, Corporate-owned stores segment includes operations with respect to all corporate-owned stores throughout the United States and Canada, and The Equipment segment includes the sale of equipment to franchisee-owned stores in the U.S. The firm generates a majority of its revenue from the Corporate-owned stores segment.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.